High CMR Rates With Ponatinib Plus Blinatumomab in Adult Ph+ ALL
Although the standard of care for Ph+ ALL results in a 5-year overall survival of up to 50%, relapse is common and are frequently driven by the T3151 mutation in BCR-ABL.
Acute Lymphocytic Leukemia
Blinatumomab Improved Survival for Patients With B-Cell ALL, but Not Significantly
Researchers sought to determine if immunotherapy including blinatumomab could improve disease-free survival for patients with B-cell ALL.
Survey Reveals Varied Treatment of VTE in Pediatric Acute Lymphocytic Leukemia
A team of researchers identified a lack of standardized practices for treating venous thromboembolism among pediatric patients with acute lymphocytic leukemia.
Anti-CD19 CAR T-Cell Therapy Effective in Relapsed/Refractory B-Cell Acute Lymphocytic Leukemia
Investigators aimed to determine and compare outcomes in patients with relapsed or refractory ALL who were treated with anti-CD19 CAR T-cell therapy.
- Loading...
Loading...
Next post in Hematologic Cancers
Loading... 
Loading...